AUTHORS
Taylor R. Brooks, MD, Brian Hill, MD, PhD2, Deepa Jagadeesh, MD, MPH3, Evandro Dantas Bezerra, MD4, Robert Dean, MD5, Allison Winter, MD6, Paolo Fabrizio Caimi, MD7
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Introduction: Epcoritamab (epco), a CD3×CD20 bispecific antibody approved for the treatment of patients (pts) with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) and follicular lymphoma (FL), causes cytokine release syndrome (CRS) in roughly half of patients, necessitating step up dosing, prophylactic steroids, and frequent (often, inpatient) monitoring. Management of CRS is reactive, rather than preventative and relies on administration of tocilizumab, which targets the anti-interleukin 6 (IL-6) receptor. Siltuximab is a monoclonal antibody that neutralizes circulating IL-6 and, unlike tocilizumab, does not raise free IL-6, potentially lowering the risk of immune effector cell-associated neurotoxicity syndrome (ICANS). We hypothesized that a single prophylactic dose of siltuximab given before epco step-up dosing would reduce CRS without compromising efficacy. Here, we report the first prospective experience utilizing this strategy.
Methods: In this single-center, prospective, single-arm clinical trial, adults with r/r LBCL or FL received one dose of siltuximab 11 mg/kg on cycle (C) 1 day (D), 30-60 minutes before epco. Participants then received standard epco step-up dosing, followed by continuation dosing until disease progression or intolerance. Participants with LBCL also could receive gemcitabine plus oxaliplatin (GemOx) in combination with epco, beginning in C2 and administered according to standard doses every 14 days. CRS and ICANS were graded by ASTCT criteria and all adverse events (AEs) by CTCAE v5. The primary endpoint was CRS incidence during C1. Investigator-assessed response was defined according to Lugano 2014 criteria. A prespecified safety analysis after 10 patients were enrolled was included.
Results: As of July 29, 2026, ten participants were treated. The median age was 68 years (interquartile range [IQR] 66-75) and 50% were female. Histology was DLBCL NOS in four (40%), high-grade B-cell lymphoma in one (10%), and FL in five (50%); no individuals with LBLC had antecedent indolent lymphoma. Most (60%) had stage III-IV disease, three participants (30%) had ECOG performance status ≥2 at the time of epco start. Participants were treated with a median of two prior lines (range 1-7) and three (30%) were refractory to the line of therapy immediately preceding epco. Three (30%) had prior CAR T-cell therapy and one had prior autologous hematopoietic progenitor cell transplant. Seven (70%) received epco monotherapy and three (30%) received epco plus GemOx. One grade 1 CRS event occurred in one participant (10%), following the 0.8 mg dose (C1D8) and resolved after a single dose of dexamethasone, without additional intervention. No ICANS of any grade occurred. Notably, no cases of CRS occurred after the first full dose of 48mg (n=9 participants completing step up) or beyond completion of step-up. Treatment-emergent AEs (TEAEs) occurred in all 10 participants, with grade 3 events in 7 (70%) and no grade 4-5 events. The most common AEs were decreased platelet count (90%), hyperkalemia (50%), and injection-site reaction (50%). Infections occurred in 3 participants (30%; grade ≥3 in 2 [20%]) with no fatal infections. No TEAEs led to treatment discontinuation.
Among eight response-evaluable participants, the overall response rate was 75% (6/8) and complete response rate 50% (4/8), with median time to response of 54 days. With a median follow-up of 4.6 months (IQR 2.9-11.5 months), the 6-month progression free and overall survival estimates are 78% (95% confidence interval [CI] 55-100%) and 100% (no deaths at 6-months), respectively, with a 6-month duration of response estimate of 100% (no progression events at or before 6-months).
Conclusions: A single prophylactic dose of siltuximab before epco is associated with a markedly lower incidence of CRS (10%, no grade ≥2, no tocilizumab) than reported for epco monotherapy (~50%), with no events beyond step-up dosing. No ICANS was observed and efficacy of treatment appears to be preserved. By directly neutralizing IL-6, siltuximab prophylaxis can significantly reduce the toxicity and monitoring burden of epco and enable safer, potentially outpatient, administration. These findings support evaluation in a larger prospective cohort to include expedited step-up dosing and other strategies that broaden the applicability of bispecific antibodies of lymphoma patients including those receiving frontline treatment.
DISCLOSURES
Taylor R. Brooks, MD: No relevant conflicts of interest to declare.